FKBP1A and breast neoplasm: Since FKBP12 has been reported to be expressed in benign and malignant vascular endothelium [16], we hypothesize that FKBP12 is expressed in breast tumor endothelium, allowing tacrolimus to inhibit breast tumor angiogenesis and tumor growth.